2. Uchida A., Sakaue K., Inoue H. Epidemiology of asthma-chronic obstructive pulmonary disease overlap (ACO). Allergol Int. 2018;67:165–71. Doi: 10.1016/j.alit.2018.02.002.

3. Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS) 2015. Accessed June 18, 2023. URL: https://ginasthma.org/wp-content/uploads/2016/01/ACOS_2015.pdf

4. Fingleton J., Hardy J., Beasley R. Treatable traits of chronic airways disease. Curr Opin Pulm Med. 2018;24(1):24–31 Doi: 10.1097/MCP.0000000000000445.

5. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2023. Accessed June 16, 2023. URL: https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf

6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of COPD. 2023. Accessed June 02, 2023.

7. Bourdin A., Suehs C.M., Marin G., et al. Asthma, COPD, and overlap in a national cohort: ACO on a gradient. J Allergy Clin Immunol. 2018;141:1516–18. Doi: 10.1016/j.jaci.2017.11.049.

8. Cataldo D., Corhay J.L., Derom E., et al. A Belgian survey on the diagnosis of asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2017;12:601–13. Doi: 10.2147/COPD.S124459.

9. Bafadhel M., Peterson S., De Blas M.A., et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med. 2018;6:117–26 Doi: 10.1016/S2213-2600(18)30006-7.

10. Tong X., Wang D., Liu S., et al. The YKL-40 protein is a potential biomarker for COPD: a meta-analysis and systematic review. Int J Chron Obstruct Pulmon Dis. 2018;13:409–18. Doi: 10.2147/COPD.S152655

11. Liu L., Zhang X., Liu Y., et al. Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations. Respir Res. 2019;20:95. Doi: 10.1186 / s12931-019-1051-912. Shirai T., Hirai K., Gon Y., et al. Combined assessment of serum periostin and YKL-40 may identify asthma-COPD overlap. J Allergy Clin Immunol. 2019;7:134–45. Doi: 10.1016 / j.jaip.2018.06.015

13. Katoh S., Ikeda M., Shirai R., et al. Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease. J Asthma. 2018;55:1052–58. Doi: 10.1080/02770903.2017.1391281.

14. Gon Y., Maruoka S., Ito R., et al. Utility of serum YKL-40 levels for identification of patients with asthma and COPD. Allergology International. 2017;66:624–26. Doi: 10.1016 / j.alit.2017.02.010.

15. Jo Y.S., Kwon S.O., Kim J., et al. Neutrophil gelatinase-associated lipocalin as a complementary biomarker for the asthma-chronic obstructive pulmonary disease overlap. J Thorac Dis. 2018;10:5047–56. Doi: 10.21037 / jtd.2018.07.86.

16. Rendell H.K., Vestibo J., Agusti A., et al. Heterogeneity within and between asthma and/or COPD diagnosed by a doctor: A NEW cohort. Int J Chron Obstruct Pulmon Dis. 2021;58:2003927. Doi: 10.1183/13993003.03927-2020.

17. Leung J.M., Sin D.D. Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. Br Med J. 2017;358:j3772. Doi: 10.1136 /bmj.j3772.

18. Hikichi M., Hashimoto S., Gon Y. Asthma and COPD overlap pathophysiology of ACO. Allergol Int. 2018;67:179–86. Doi: 10.1016/j.alit.2018.01.001.

19. Postma DS, Weiss ST, van den Berge M, et al. Revisiting the Dutch hypothesis. J Allergy Clin Immunol. 2015;136:521–29. Doi: 10.1016/j.jaci.2015.06.018.

20. Sahu A., Swaroop S., Kant S., et al. Signatures for chronic obstructive pulmonary disease (COPD) and asthma: A comparative genetic analysis. J Biomed Sci. 2021;78:177–83. Doi: 10.1080/09674845.2021.1905988.

21. Hobbs B.D., de Jong K., Lamontagne M., et al. Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis. Nat Genet. 2017;49:426–32. Doi: 10.1038/ng.3752.

22. Christenson S.A., Steiling K., van den Berge M., et al. Asthma-COPD overlap. Clinical relevance of genomic signatures of type 2 inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191:758–66 Doi: 10.1164/rccm.201408-1458OC.

23. Padrаo Е., Araujo D., Todo Bom A., et al. Asthma-COPD overlap: A Portuguese survey. Pulmonology. 2018;24(3):173–81. Doi: 10.1016/j.rppnen.2017.11.009.

24. Lim H.S., Choi S.M., Lee J., et al. Responsiveness to inhaled corticosteroid treatment in patients with asthma-chronic obstructive pulmonary disease overlap syndrome. Ann Allergy Asthma Immunol. 2014;113:652–57. Doi: 10.1016 / j.anai.2014.08.021.

25. Lee S.Y., Park H.Y., Kim E.K., et al. Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma-COPD overlap syndrome. Int J Chron Obstruct Pulmon Dis. 2016;11:2797–803. Doi: 10.2147/COPD.S114964.

26. Su V.Y., Yang K.Y., Yang Y.H., et al. Use of ICS/LABA combinations or LAMA is associated with a lower risk of acute exacerbation in patients with coexistent COPD and asthma. J Allergy Clin Immunol. 2018;6:1927–35. Doi: 10.1016/j.jaip.2018.01.035.

27. Hanania N.A., Chipps B.E., Griffin N.M., et al. Omalizumab effectiveness in asthma-COPD overlap: Post hoc analysis of PROSPERO. J Allergy Clin Immunol. 2019;143:1629–33.e2. Doi: 10.1016/j.jaci.2018.11.032.

28. Kuprys-Lipinska I., Palczynski C., Molinska J., et al. Omalizumab therapy in a patient with severe asthma and co-existing chronic obstructive pulmonary disease. Postepy Dermatologii I Alergologii. 2019;36:239–41. Doi: 10.5114/ada.2018.73140

29. Pavord I.D., Chanez P., Criner G.J., et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J Med. 2017;377:1613–29. Doi: 10.1056/NEJMoa1708208.

30. Pavord I.D., Chapman K.R., Bafadhel M., et al. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO. Int J Chron Obstruct Pulmon Dis. 2021;16:1755–70. Doi: 10.2147/COPD.S294333

31. Criner G.J., Celli B.R., Brightling C.E., et al. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med. 2019;381:1023–34. Doi: 10.1056/NEJMoa1905248.